Immunology
Granulomatosis With Polyangiitis
23
Pipeline Programs↗
9
Active Trials↗
13
Companies Involved↗
Granulomatosis with Polyangiitis is an emerging landscape with 23 programs across 13 companies. The most active players are AstraZeneca, NS Pharma, Immunex. 1 therapy is approved with 11 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 311
Approved1
Analysis
Modality Breakdown
23programs
Small molecule1252%
Monoclonal antibody939%
Protein / enzyme29%
Modality classified for 100% of 23 pipeline programs.
Analysis
Trial Status
20
clinical trials
Completed8 · 40%
Recruiting3 · 15%
Not yet recruiting3 · 15%
Unknown status2 · 10%
Active, not recruiting2 · 10%
Enrolling by invitation1 · 5%
Other1 · 5%
Clinical Trials
Trial Activity
20 trials
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Not yet recruiting·—·Phase 2/3·NCT07176546·30 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)